Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA

This article was originally published here

The FDA indicated that efficacy data from an additional clinical trial will be needed to support a resubmission. Kala continues to enroll patients in its ongoing STRIDE 3

The post Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply